HROW Stock Price Chart
HROW Financial
Harrow Inc
$39.45
-3.04%
$-1.23
At close: Aug 11, 16:00:00 GMT-4
$39.94
1.24%
$0.48
Post-market: Aug 11, 20:00:00 GMT-4
Back
Harrow Inc (HROW) Financial
Key Stats
Prev.Close
$40.69
Open
$39.99
Day's Range
$38.32 - $42.56
52 week range
$28.54 - $54.85
Volume
1.8M
Avg.Volume
711.7K
Dividend yield
--
EPS (TTM)
-0.41
Market Cap
$1.4B
What is HROW?
Harrow, Inc. engages in the development, production, and sale of innovative medications. The company is headquartered in Nashville, Tennessee and currently employs 382 full-time employees. The company went IPO on 2013-02-08. The firm offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. The company owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. The company owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. The company owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
